| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.35B | 18.28 | 22.57 | 65.15% | 42.87% | 48.57% | 2.53% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 86.21M | 2.90 | -0.23 | -49.37% | 0.24 | |||
| INOInovio Pharmaceuticals, Inc. | 112.67M | 1.64 | -0.42 | -73.83% | -592.82% | -115.42% | 0.17 | |
| ALGSAligos Therapeutics, Inc. | 48.45M | 9.05 | -0.43 | -74.6% | -32.68% | -120.37% | ||
| BRNSBarinthus Biotherapeutics plc | 30.83M | 0.76 | -0.49 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.99M | 1.16 | -0.67 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 172.81M | 9.24 | -0.79 | -170.84% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.18M | 10.66M | 22.76M | 16.99M | 29.35M | 42.22M | 80.94M | 154.08M | 258.21M | 426.45M |
| Revenue Growth % | 0.21% | 0.49% | 1.13% | -0.25% | 0.73% | 0.44% | 0.92% | 0.9% | 0.68% | 0.65% |
| Cost of Goods Sold | 4.31M | 6.36M | 29.16M | 42.19M | 39.5M | 61.29M | 79.77M | 118.81M | 169.27M | 206.9M |
| COGS % of Revenue | 0.6% | 0.6% | 1.28% | 2.48% | 1.35% | 1.45% | 0.99% | 0.77% | 0.66% | 0.49% |
| Gross Profit | 2.87M | 4.3M | -6.4M | -25.21M | -10.16M | -19.07M | 1.17M | 35.27M | 88.94M | 219.55M |
| Gross Margin % | 0.4% | 0.4% | -0.28% | -1.48% | -0.35% | -0.45% | 0.01% | 0.23% | 0.34% | 0.51% |
| Gross Profit Growth % | 0.32% | 0.5% | -2.49% | -2.94% | 0.6% | -0.88% | 1.06% | 29.06% | 1.52% | 1.47% |
| Operating Expenses | 18.38M | 21.63M | 32.06M | 35.08M | 31.27M | 45.84M | 59.55M | 74.63M | 67.31M | 80.57M |
| OpEx % of Revenue | 2.56% | 2.03% | 1.41% | 2.07% | 1.07% | 1.09% | 0.74% | 0.48% | 0.26% | 0.19% |
| Selling, General & Admin | 6.75M | 8.49M | 18.09M | 22.5M | 25.91M | 35.05M | 42.9M | 52.46M | 59.02M | 74.12M |
| SG&A % of Revenue | 0.94% | 0.8% | 0.79% | 1.32% | 0.88% | 0.83% | 0.53% | 0.34% | 0.23% | 0.17% |
| Research & Development | 7.02M | 7.69M | 6.23M | 3.93M | 2.34M | 5.91M | 3.65M | 3.61M | 3.3M | 1.81M |
| R&D % of Revenue | 0.98% | 0.72% | 0.27% | 0.23% | 0.08% | 0.14% | 0.05% | 0.02% | 0.01% | 0% |
| Other Operating Expenses | 4.62M | 4.5K | -10.14K | -127.12K | 3.01M | 4.89M | 13M | 18.56M | 4.99M | 4.63M |
| Operating Income | -15.51M | -17.33M | -39.31M | -60.29M | -41.42M | -64.91M | -58.37M | -39.37M | 21.63M | 138.98M |
| Operating Margin % | -2.16% | -1.63% | -1.73% | -3.55% | -1.41% | -1.54% | -0.72% | -0.26% | 0.08% | 0.33% |
| Operating Income Growth % | 0.03% | -0.12% | -1.27% | -0.53% | 0.31% | -0.57% | 0.1% | 0.33% | 1.55% | 5.42% |
| EBITDA | -15.04M | -16.86M | -38.08M | -56.84M | -38.17M | -60.97M | -52.88M | -32.25M | 29.96M | 147.03M |
| EBITDA Margin % | -2.1% | -1.58% | -1.67% | -3.35% | -1.3% | -1.44% | -0.65% | -0.21% | 0.12% | 0.34% |
| EBITDA Growth % | 0.05% | -0.12% | -1.26% | -0.49% | 0.33% | -0.6% | 0.13% | 0.39% | 1.93% | 3.91% |
| D&A (Non-Cash Add-back) | 469.82K | 469.58K | 1.23M | 3.45M | 3.26M | 3.94M | 5.5M | 7.11M | 8.33M | 8.04M |
| EBIT | -16.13M | -17.28M | -40.47M | -60.22M | -39.29M | -63.76M | -58.59M | -46.63M | -3.21M | 139.64M |
| Net Interest Income | -1.8M | -2.19M | -3.23M | -5.33M | -8.19M | -11.7M | -13.02M | -19.23M | -23.41M | -11.83M |
| Interest Income | 37.83K | 50.32K | 57.23K | 195.4K | 800.78K | 288.13K | 34.53K | 44.83K | 1.62M | 2.1M |
| Interest Expense | 1.84M | 2.24M | 3.29M | 5.52M | 8.99M | 11.99M | 13.06M | 19.28M | 25.03M | 13.93M |
| Other Income/Expense | -2.46M | -2.18M | -4.45M | -5.45M | -6.85M | -10.83M | -13.27M | -26.54M | -49.87M | -13.27M |
| Pretax Income | -17.97M | -19.52M | -43.76M | -65.74M | -48.28M | -75.75M | -71.65M | -65.9M | -28.24M | 125.71M |
| Pretax Margin % | -2.5% | -1.83% | -1.92% | -3.87% | -1.65% | -1.79% | -0.89% | -0.43% | -0.11% | 0.29% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -71.96M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1.57% |
| Net Income | -17.97M | -19.52M | -43.76M | -65.74M | -48.28M | -75.75M | -71.65M | -65.9M | -28.24M | 197.67M |
| Net Margin % | -2.5% | -1.83% | -1.92% | -3.87% | -1.65% | -1.79% | -0.89% | -0.43% | -0.11% | 0.46% |
| Net Income Growth % | -0.07% | -0.09% | -1.24% | -0.5% | 0.27% | -0.57% | 0.05% | 0.08% | 0.57% | 8% |
| Net Income (Continuing) | -17.97M | -19.52M | -43.76M | -65.74M | -48.28M | -75.75M | -71.65M | -65.9M | -28.24M | 197.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.73 | -1.61 | -1.91 | -1.45 | -1.05 | -1.02 | -0.61 | -0.43 | -0.13 | 0.81 |
| EPS Growth % | 0.04% | 0.07% | -0.19% | 0.24% | 0.28% | 0.03% | 0.4% | 0.3% | 0.7% | 7.23% |
| EPS (Basic) | -1.73 | -1.61 | -1.91 | -1.45 | -1.05 | -1.02 | -0.61 | -0.43 | -0.13 | 0.85 |
| Diluted Shares Outstanding | 10.41M | 12.15M | 22.9M | 45.19M | 54.35M | 86.15M | 139.58M | 197.87M | 223.98M | 243.34M |
| Basic Shares Outstanding | 10.41M | 12.15M | 22.9M | 45.19M | 54.35M | 86.15M | 139.58M | 197.87M | 223.98M | 233.08M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 21.29M | 21.66M | 63.17M | 44.53M | 85.82M | 153.74M | 208.73M | 270.4M | 257.01M | 331.41M |
| Cash & Short-Term Investments | 16.81M | 15.31M | 43.11M | 22.75M | 26.75M | 55.92M | 51.09M | 86.52M | 51.35M | 103.15M |
| Cash Only | 10.44M | 9.91M | 43.11M | 22.75M | 26.75M | 55.92M | 51.09M | 86.52M | 51.35M | 103.15M |
| Short-Term Investments | 6.37M | 5.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 924.47K | 1.02M | 3.88M | 1.39M | 3.47M | 13.24M | 28.58M | 15.51M | 27.42M | 50M |
| Days Sales Outstanding | 47.01 | 34.85 | 62.22 | 29.92 | 43.15 | 114.44 | 128.86 | 36.73 | 38.76 | 42.79 |
| Inventory | 3.45M | 5.02M | 12.63M | 18.62M | 53.06M | 81.54M | 124.72M | 163.28M | 172.91M | 170.24M |
| Days Inventory Outstanding | 291.71 | 288.07 | 158.05 | 161.04 | 490.29 | 485.56 | 570.69 | 501.6 | 372.83 | 300.32 |
| Other Current Assets | 0 | 0 | 2.05M | 1.77M | 0 | 0 | 0 | 5.09M | 5.33M | 8.03M |
| Total Non-Current Assets | 2.42M | 2.03M | 44.85M | 44.35M | 41.27M | 53.93M | 67.52M | 78.06M | 72.17M | 157.27M |
| Property, Plant & Equipment | 2.4M | 2M | 30.47M | 30.12M | 32.99M | 45.85M | 58.2M | 68.75M | 63.47M | 63.34M |
| Fixed Asset Turnover | 2.99x | 5.33x | 0.75x | 0.56x | 0.89x | 0.92x | 1.39x | 2.24x | 4.07x | 6.73x |
| Goodwill | 0 | 0 | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M |
| Intangible Assets | 0 | 0 | 4.85M | 4M | 3.16M | 2.44M | 1.73M | 1.01M | 499K | 460K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 27.16K | 27.16K | 6.01M | 6.7M | 1.6M | 2.11M | 4.07M | 4.77M | 4.67M | 5.66M |
| Total Assets | 23.71M | 23.69M | 108.02M | 88.88M | 127.09M | 207.67M | 276.25M | 348.46M | 329.18M | 488.68M |
| Asset Turnover | 0.30x | 0.45x | 0.21x | 0.19x | 0.23x | 0.20x | 0.29x | 0.44x | 0.78x | 0.87x |
| Asset Growth % | -0.13% | -0% | 3.56% | -0.18% | 0.43% | 0.63% | 0.33% | 0.26% | -0.06% | 0.48% |
| Total Current Liabilities | 4.22M | 11.22M | 9.44M | 9.63M | 14.03M | 19.95M | 30.38M | 39.27M | 49.81M | 55.54M |
| Accounts Payable | 2.09M | 2.56M | 5.92M | 5.9M | 9.17M | 11.07M | 12.43M | 13.23M | 15.66M | 20.22M |
| Days Payables Outstanding | 176.75 | 147.17 | 74.1 | 51.04 | 84.77 | 65.95 | 56.87 | 40.64 | 33.77 | 35.67 |
| Short-Term Debt | 15.14K | 6.11M | 0 | 29.98K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 145.15K | 145.15K | 142.83K | 142.83K | 142.83K | 142.83K | 142.83K | 143K | 182K | 143K |
| Other Current Liabilities | -30.28K | 0 | 0 | -59.97K | 0 | 207.26K | 16.05M | 1.8M | 2.37M | 1.85M |
| Current Ratio | 5.05x | 1.93x | 6.69x | 4.63x | 6.12x | 7.71x | 6.87x | 6.89x | 5.16x | 5.97x |
| Quick Ratio | 4.23x | 1.48x | 5.35x | 2.69x | 2.34x | 3.62x | 2.77x | 2.73x | 1.69x | 2.90x |
| Cash Conversion Cycle | 161.97 | 175.76 | 146.17 | 139.92 | 448.68 | 534.05 | 642.68 | 497.69 | 377.83 | 307.44 |
| Total Non-Current Liabilities | 18.68M | 16.92M | 58.25M | 59.48M | 86.87M | 99.48M | 104.7M | 157.22M | 144.17M | 84.12M |
| Long-Term Debt | 15.72M | 14.11M | 42.97M | 44.08M | 83.2M | 92.97M | 94.87M | 142.83M | 130.59M | 72.34M |
| Capital Lease Obligations | 36.26K | 0 | 0 | 119.08K | 1.3M | 4.33M | 7.46M | 10.7M | 9.78M | 8.56M |
| Deferred Tax Liabilities | -16.3M | -7.98M | 0 | -40.53M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 92.42K | 117.81K | 12.73M | 12.88M | 106.57K | 54.89K | 397.35K | 1.85M | 2.11M | 1.67M |
| Total Liabilities | 22.89M | 28.14M | 67.69M | 69.11M | 100.9M | 119.42M | 135.08M | 196.49M | 193.98M | 139.66M |
| Total Debt | 15.73M | 20.26M | 42.97M | 44.22M | 84.73M | 97.67M | 102.92M | 154.44M | 141.42M | 82.12M |
| Net Debt | 5.29M | 10.34M | -136.72K | 21.47M | 57.98M | 41.75M | 51.83M | 67.92M | 90.07M | -21.03M |
| Debt / Equity | 19.16x | - | 1.07x | 2.24x | 3.23x | 1.11x | 0.73x | 1.02x | 1.05x | 0.24x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 4.72x | 0.56x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 3.01x | -0.14x |
| Interest Coverage | -8.42x | -7.74x | -11.96x | -10.92x | -4.61x | -5.42x | -4.47x | -2.04x | 0.86x | 9.98x |
| Total Equity | 820.97K | -4.46M | 40.33M | 19.77M | 26.19M | 88.25M | 141.17M | 151.97M | 135.21M | 349.02M |
| Equity Growth % | -0.86% | -6.43% | 10.05% | -0.51% | 0.32% | 2.37% | 0.6% | 0.08% | -0.11% | 1.58% |
| Book Value per Share | 0.08 | -0.37 | 1.76 | 0.44 | 0.48 | 1.02 | 1.01 | 0.77 | 0.60 | 1.43 |
| Total Shareholders' Equity | 820.97K | -4.46M | 40.33M | 19.77M | 26.19M | 88.25M | 141.17M | 151.97M | 135.21M | 349.02M |
| Common Stock | 1.07K | 1.29K | 4.53K | 4.63K | 5.93K | 10.49K | 19.58K | 22K | 23K | 24K |
| Retained Earnings | -87.42M | -106.93M | -150.69M | -216.44M | -264.72M | -340.47M | -412.11M | -478.02M | -506.26M | -308.58M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.75M | -2.22M | -1.29M | -3.42M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.42M | -18.27M | -37.27M | -62.68M | -76.19M | -102M | -112.37M | -59.51M | 8.8M | 118.67M |
| Operating CF Margin % | -2.15% | -1.71% | -1.64% | -3.69% | -2.6% | -2.42% | -1.39% | -0.39% | 0.03% | 0.28% |
| Operating CF Growth % | -0.05% | -0.18% | -1.04% | -0.68% | -0.22% | -0.34% | -0.1% | 0.47% | 1.15% | 12.49% |
| Net Income | -17.97M | -19.52M | -43.76M | -65.74M | -48.28M | -75.75M | -71.65M | -65.9M | -28.24M | 197.67M |
| Depreciation & Amortization | 469.82K | 469.58K | 2.69M | 3.45M | 3.26M | 3.94M | 5.5M | 7.11M | 8.33M | 8.04M |
| Stock-Based Compensation | 1.71M | 1.25M | 1.56M | 0 | 2.65M | 2.86M | 3.49M | 5.21M | 6.19M | 13.62M |
| Deferred Taxes | 651.24K | 0 | 1.88M | 122.19K | 0 | -910.1K | 220.76K | 0 | 0 | -84.28M |
| Other Non-Cash Items | 390.54K | 534.11K | 638.73K | 961.33K | -320.34K | 1.64M | 1.75M | 12.35M | 32.64M | 2.16M |
| Working Capital Changes | -671.12K | -1.01M | -282.24K | -3.69M | -33.5M | -33.78M | -51.68M | -18.29M | -10.12M | -18.54M |
| Change in Receivables | -540.51K | -93.56K | -2.86M | 2.49M | -2.08M | -9.77M | -15.34M | 13.07M | -11.92M | -22.58M |
| Change in Inventory | -1.74M | -1.57M | 589.32K | -5.99M | -34.65M | -28.47M | -43.19M | -38.56M | -9.63M | 2.67M |
| Change in Payables | 308.66K | 476.83K | 2.81M | -20.48K | 3.27M | 1.9M | 1.36M | 799.98K | 3.84M | 4.15M |
| Cash from Investing | -1.74M | 904.58K | 15.21M | -2.1M | -3.81M | -12.72M | -13.51M | -13.91M | -4.98M | -8.57M |
| Capital Expenditures | -26.07K | -73.41K | -2.68M | -2.1M | -3.81M | -12.73M | -13.51M | -13.91M | -4.77M | -8.23M |
| CapEx % of Revenue | 0% | 0.01% | 0.12% | 0.12% | 0.13% | 0.3% | 0.17% | 0.09% | 0.02% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 12.5M | 0 | 0 | 2K | 0 | 0 | -210K | -349K |
| Cash from Financing | 10.4M | 16.84M | 60.75M | 42.92M | 80M | 143.9M | 121.05M | 108.85M | -38.99M | -58.3M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 9.72M | -47.1K | -3.43M | 13.01K | -10.86M | -816.57K | -62K | -7.51M | -13.97M | -5.8M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -15.44M | -18.34M | -39.95M | -64.77M | -80.01M | -114.73M | -125.88M | -73.42M | 3.82M | 110.1M |
| FCF Margin % | -2.15% | -1.72% | -1.76% | -3.81% | -2.73% | -2.72% | -1.56% | -0.48% | 0.01% | 0.26% |
| FCF Growth % | 0.09% | -0.19% | -1.18% | -0.62% | -0.24% | -0.43% | -0.1% | 0.42% | 1.05% | 27.83% |
| FCF per Share | -1.48 | -1.51 | -1.74 | -1.43 | -1.47 | -1.33 | -0.90 | -0.37 | 0.02 | 0.45 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.94x | 0.85x | 0.95x | 1.58x | 1.35x | 1.57x | 0.90x | -0.31x | 0.60x |
| Interest Paid | 0 | 0 | 0 | 0 | 8.11M | 0 | 0 | 0 | 18.05M | 10.67M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.39M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -526.23% | - | -243.95% | -218.77% | -210.08% | -132.38% | -62.46% | -44.96% | -19.67% | 81.65% |
| Return on Invested Capital (ROIC) | -235.29% | -216.68% | -127.95% | -111.05% | -49.55% | -45.47% | -27.11% | -14.3% | 7.29% | 37.68% |
| Gross Margin | 39.93% | 40.34% | -28.14% | -148.42% | -34.6% | -45.17% | 1.45% | 22.89% | 34.44% | 51.48% |
| Net Margin | -250.36% | -183.05% | -192.26% | -387.06% | -164.5% | -179.41% | -88.52% | -42.77% | -10.94% | 46.35% |
| Debt / Equity | 19.16x | - | 1.07x | 2.24x | 3.23x | 1.11x | 0.73x | 1.02x | 1.05x | 0.24x |
| Interest Coverage | -8.42x | -7.74x | -11.96x | -10.92x | -4.61x | -5.42x | -4.47x | -2.04x | 0.86x | 9.98x |
| FCF Conversion | 0.86x | 0.94x | 0.85x | 0.95x | 1.58x | 1.35x | 1.57x | 0.90x | -0.31x | 0.60x |
| Revenue Growth | 21.34% | 48.53% | 113.49% | -25.37% | 72.79% | 43.85% | 91.72% | 90.36% | 67.58% | 65.15% |
| 2013 | 2014 | 2015 | 2016 | 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing | - | - | - | - | - | - | - | 161.16M | 415.81M |
| ADMA BioManufacturing Growth | - | - | - | - | - | - | - | - | 158.01% |
| Plasma Collection Centers | - | - | - | - | - | - | - | 8.12M | 11.3M |
| Plasma Collection Centers Growth | - | - | - | - | - | - | - | - | 39.18% |
| Product Revenue | - | - | - | - | - | 80.8M | 153.94M | - | - |
| Product Revenue Growth | - | - | - | - | - | - | 90.52% | - | - |
| License Revenue | - | - | - | - | - | 142.83K | 142.83K | - | - |
| License Revenue Growth | - | - | - | - | - | - | 0.00% | - | - |
| ADMA BioManufacturing | - | - | - | - | 22.18M | - | - | - | - |
| ADMA BioManufacturing Growth | - | - | - | - | - | - | - | - | - |
| Plasma Collection Centers | - | - | 7.05M | 10.52M | 7.03M | - | - | - | - |
| Plasma Collection Centers Growth | - | - | - | 49.19% | -33.17% | - | - | - | - |
| Corporate | - | 75.56K | 127.35K | 142.83K | 142.83K | - | - | - | - |
| Corporate Growth | - | - | 68.55% | 12.16% | 0.00% | - | - | - | - |
| Research And Development | - | - | - | - | - | - | - | - | - |
| Research And Development Growth | - | - | - | - | - | - | - | - | - |
| Plasma Collection Center | - | 5.84M | - | - | - | - | - | - | - |
| Plasma Collection Center Growth | - | - | - | - | - | - | - | - | - |
| Plasma Collection Center Member | 3.02M | - | - | - | - | - | - | - | - |
| Plasma Collection Center Member Growth | - | - | - | - | - | - | - | - | - |
| Corporate Member | 44.07K | - | - | - | - | - | - | - | - |
| Corporate Member Growth | - | - | - | - | - | - | - | - | - |
| Research And Development Member | - | - | - | - | - | - | - | - | - |
| Research And Development Member Growth | - | - | - | - | - | - | - | - | - |
| 2013 | 2014 | 2015 | 2016 | 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| United States | - | - | - | - | - | - | 146.43M | - | 410.15M |
| United States Growth | - | - | - | - | - | - | - | - | - |
| International | - | - | - | - | - | - | - | - | 16.31M |
| International Growth | - | - | - | - | - | - | - | - | - |
ADMA Biologics, Inc. (ADMA) has a price-to-earnings (P/E) ratio of 22.6x. This is roughly in line with market averages.
ADMA Biologics, Inc. (ADMA) reported $488.6M in revenue for fiscal year 2024.
ADMA Biologics, Inc. (ADMA) grew revenue by 65.2% over the past year. This is strong growth.
Yes, ADMA Biologics, Inc. (ADMA) is profitable, generating $209.4M in net income for fiscal year 2024 (46.4% net margin).
ADMA Biologics, Inc. (ADMA) has a return on equity (ROE) of 81.6%. This is excellent, indicating efficient use of shareholder capital.
ADMA Biologics, Inc. (ADMA) generated $40.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.